STALLERGENES-GREER
Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), announced today that it has signed global agreements with Nestlé to harness the peanut allergy oral immunotherapy treatment Palforzia®. The transaction was closed upon signing.
Peanut allergy currently affects approximately 2% of the general population of Western nations1, and the prevalence of peanut allergy doubled among children between 2005 and 20152. The difficulty of avoiding peanuts, combined with the severity of allergic reactions, including anaphylaxis, shows the need for effective treatment3.
“We are delighted about this agreement with Nestlé which marks a significant milestone for Stallergenes Greer,” stated Michele Antonelli, CEO of Stallergenes Greer. “Palforzia®, with its robust efficacy and safety profile, is currently the only available approved treatment for inadvertent exposure to peanuts. By entering the food allergy space, Stallergenes Greer becomes the first allergen immunotherapy company to offer both respiratory and food allergy treatments and demonstrates its lasting commitment to provide patients and the medical community with innovative allergen immunotherapy treatments.”
Nestlé will receive milestone payments and ongoing royalties from Stallergenes Greer. There will be a customary transition period to ensure business continuity and give patients uninterrupted access to the treatment.
With this transaction, Stallergenes Greer further strengthens its presence in the field of AIT. The company’s portfolio offers patients and healthcare professionals precise personalised AIT treatments which cover a broad range of administration modes and can be tailored to the individual needs of patients with allergies: sublingual oral solutions, tablets, and injectables for respiratory allergies; and powder to be consumed with semi-solid foods for peanut allergies.
ABOUT PALFORZIA®
Palforzia® is an oral immunotherapy treatment approved for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy by the U.S. Food and Drug Administration (FDA), the European Commission (EC), the Medicines and Healthcare products Regulatory Agency (MHRA) in the U.K., and by Swissmedic. Use of Palforzia® may be continued in patients 18 years of age and older.
Palforzia® is not indicated for the emergency treatment of allergic reactions, including anaphylaxis, and must always be used in conjunction with a peanut-avoidant diet.
ABOUT STALLERGENES GREER INTERNATIONAL AG
Headquartered in Baar (Switzerland), Stallergenes Greer International AG is a global healthcare company specialising in the diagnosis and treatment of allergies through the research, development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer International AG is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France). For more information, visit www.stallergenesgreer.com.
1 The global burden of illness of peanut allergy: A comprehensive literature review. Jay A. Lieberman, Ruchi S Gupta, Rebecca C. Knibb, Tmirah Haselkorn, Stephen Tilles, Douglas P. Mack, and Guillaume Pouessel. Online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247890/. Accessed August 31, 2023
2 Du Toit G, et al. Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy. N Engl J Med 2015; 372: 803-13. Accessed August 31, 2023.
3 Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191-3. Accessed August 31, 2023.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230903080283/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lattice and Mitsubishi Electric Collaborate to Deliver Next-Gen Industrial Automation Experiences17.7.2025 08:30:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its low power Lattice CertusPro™-NX FPGAs now enable Mitsubishi Electric’s Computerized Numerical Controller (CNC) solutions to bring power efficient and reliable factory automation experiences. This collaboration was announced at the Lattice APAC Tech Summit in Tokyo, where Mitsubishi Electric participated as a guest keynote speaker. Hosted today, Lattice APAC Tech Summit showcased the company’s latest low power FPGA technology with industry leaders including Mitsubishi Electric, Desay, Furukawa AS, Glory LTD, LIPS, and NXP alongside more than 150 customers and partners in the APAC region. Mitsubishi Electric’s industry-leading CNC solutions leverage the cutting-edge interface bridging capabilities of Lattice CertusPro-NX FPGAs to create high accuracy, adaptability, and efficient real-time processing. These features are ideal for a variety of Industrial applications, including machine building, Au
SES Completes Acquisition of Intelsat, Creating Global Multi-Orbit Connectivity Powerhouse17.7.2025 07:30:00 CEST | Press release
New leading multi-orbit space company with a network of 120 GEO+MEO satellites and access to LEO constellations enables SES to better serve its customers SES, a leading space solutions company, today announced the completion of its highly value accretive acquisition of Intelsat, creating a strengthened global satellite operator with an expanded fleet of 120 satellites across two orbits. The newly combined company will leverage its skilled teams with deep vertical expertise to deliver integrated multi-orbit, multi-band satellite and connectivity solutions to businesses and governments around the world, creating a stronger multi-orbit operator with ~60% of revenue in high-growth segments. With a world-class network including approximately 90 geostationary (GEO), nearly 30 medium earth orbit (MEO) satellites, strategic access to low earth orbit (LEO) satellites, and an extensive ground network, SES can now deliver connectivity solutions utilising complementary spectrum bands including C-,
Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction With Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss17.7.2025 07:00:00 CEST | Press release
Final data from a first-of-its-kind clinical trial confirm that the combination of Sculptra® and Restylane® Lyft™ or Contour™* delivers sustained improvement in facial aesthetic appearance for patients experiencing facial volume loss due to medication-driven weight loss1 Following interim analysis at three months presented earlier this year, a six-month extension study was conducted to capture the durability of treatment effects after nine months1 Galderma continues to lead the response to addressing the aesthetic concerns of patients experiencing medication-driven weight loss, leveraging its deep dermatological expertise and working closely with healthcare professionals to meet evolving patient needs Galderma has revealed positive final data from a phase IV first-of-its-kind trial exploring the benefits of Restylane Lyft or Contour in combination with Sculptrato address the aesthetic concerns of patients experiencing facial volume loss associated with medication-driven weight loss.1 T
Global New Material International: Driving a Green Future Through Innovation17.7.2025 04:41:00 CEST | Press release
As global economic integration accelerates, materials science—the foundation of modern industry—is undergoing a profound transformation. Global New Material International Holdings Limited (GNMI) stands at the forefront of this evolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716430383/en/ Colored Building-Integrated Photovoltaic modules developed by CQV, a subsidiary of GNMI. At the recent 2nd Sino-European Corporate ESG Best Practice Conference, GNMI was honored with the “Best Practice in Technological Innovation” award for its outstanding commitment to innovation and green development. The judging panel praised the company’s achievements, noting that “GNMI’s innovations have gained broad international recognition. With a clear strategy focused on green manufacturing and sustainability, the company offers viable solutions to reduce dependence on non-renewable resources while advancing eco-friendly production.” T
Andersen Consulting styrker sin platform med tilføjelsen af Baufest16.7.2025 20:07:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Baufest, et globalt firma inden for digitalt produktdesign og -udvikling. Med mere end 30 års erfaring og kontorer i hele Amerika og Europa er Baufest anerkendt for at kombinere banebrydende teknologi med en dybdegående forståelse af forretningsstrategi og brugeroplevelse. Firmaet tilbyder et omfattende udvalg af tjenester, der omfatter forretningsdesign, udvikling af digitale produkter, data og anvendt AI og cybersikkerhed. Baufest betjener virksomhedskunder på tværs af nøgleindustrier som bank og finans, detailhandel, energi og sundhedspleje med fokus på at skabe målbare forretningsresultater gennem smidig, skalerbar og etisk teknologipraksis. "Vores samarbejde med Andersen Consulting er et vigtigt skridt fremad for de tjenester, vi tilbyder," siger Ángel Pérez Puletti, administrerende direktør for Baufest. "Andersens fulde pakke af specialiserede tjenester bygger på Baufests
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom